A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Spring takes a hike - for the time being
A number of Britons are feared stranded on Mount Everest after the Nepal earthquake triggered a deadly avalanche on Saturday.
Prime Minister defends royals' decision to give birth in a private hospital - instead of going with the NHS